Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

PubWeight™: 8.63‹?› | Rank: Top 0.1%

🔗 View Article (PMID 25034862)

Published in Lancet on July 15, 2014


Caroline Robert1, Antoni Ribas2, Jedd D Wolchok3, F Stephen Hodi4, Omid Hamid5, Richard Kefford6, Jeffrey S Weber7, Anthony M Joshua8, Wen-Jen Hwu9, Tara C Gangadhar10, Amita Patnaik11, Roxana Dronca12, Hassane Zarour13, Richard W Joseph14, Peter Boasberg5, Bartosz Chmielowski2, Christine Mateus15, Michael A Postow3, Kevin Gergich16, Jeroen Elassaiss-Schaap16, Xiaoyun Nicole Li16, Robert Iannone16, Scot W Ebbinghaus16, S Peter Kang16, Adil Daud17

Author Affiliations

1: Gustave Roussy and INSERM U981, Paris-Sud, France. Electronic address:
2: University of California Los Angeles, Los Angeles, CA, USA.
3: Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
4: Dana-Farber Cancer Institute, Boston, MA, USA.
5: Angeles Clinic and Research Institute, Los Angeles, CA, USA.
6: Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Westmead, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
7: H Lee Moffitt Cancer Center, Tampa, FL, USA.
8: Princess Margaret Cancer Centre, Toronto, ON, Canada.
9: University of Texas MD Anderson Cancer Center, Houston, TX, USA.
10: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
11: South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.
12: Mayo Clinic, Rochester, MN, USA.
13: University of Pittsburgh, Pittsburgh, PA, USA.
14: Mayo Clinic, Jacksonville, FL, USA.
15: Gustave Roussy and INSERM U981, Paris-Sud, France.
16: Merck, Whitehouse Station, NJ, USA.
17: University of California San Francisco, San Francisco, CA, USA.

Associated clinical trials:

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) | NCT01295827

Articles citing this

(truncated to the top 100)

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol (2015) 2.38

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol (2016) 1.89

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One (2015) 1.73

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol (2016) 1.70

The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J (2015) 1.69

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53

Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 1.50

Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47

Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45

Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol (2015) 1.43

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol (2016) 1.39

Cancer: Antitumour immunity gets a boost. Nature (2014) 1.28

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol (2015) 1.27

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer (2015) 1.24

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res (2015) 1.18

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol (2016) 1.17

PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16

Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol (2015) 1.15

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res (2015) 1.14

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14

Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res (2015) 1.09

Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.09

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol (2015) 1.07

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol (2016) 1.06

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06

Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05

Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget (2015) 1.02

New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci (2015) 1.02

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer (2016) 1.01

Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res (2014) 1.01

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01

Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer (2016) 1.00

Pembrolizumab. J Immunother Cancer (2015) 0.99

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99

Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. CPT Pharmacometrics Syst Pharmacol (2016) 0.99

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT Pharmacometrics Syst Pharmacol (2016) 0.99

Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98

Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT Pharmacometrics Syst Pharmacol (2016) 0.98

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. J Hematol Oncol (2014) 0.97

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res (2016) 0.97

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 0.97

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun (2016) 0.97

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov (2016) 0.96

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res (2016) 0.94

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget (2016) 0.94

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT Pharmacometrics Syst Pharmacol (2016) 0.93

The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer (2016) 0.92

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91

Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91

Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging (2015) 0.91

Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther (2015) 0.90

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci (2016) 0.90

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med (2014) 0.90

PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight (2016) 0.90

Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant (2015) 0.89

Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol (2015) 0.89

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer (2016) 0.89

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89

Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther (2015) 0.88

Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer (2015) 0.88

Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer (2014) 0.88

A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget (2015) 0.88

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol (2015) 0.87

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J (2015) 0.87

Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87

Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer (2015) 0.87

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res (2015) 0.87

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer (2016) 0.87

Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med (2015) 0.87

Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. Mol Cancer Res (2015) 0.86

Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86

Tumor localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res (2017) 0.85

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol (2015) 0.85

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. J Clin Med Res (2015) 0.85

Increased treatment-related toxicity subsequent to an anti-PD-1 agent. Curr Oncol (2015) 0.85

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci (2016) 0.85

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget (2016) 0.85

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84

Articles by these authors

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol (2016) 1.77

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 1.02

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer (2014) 0.84

Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol (2014) 0.77

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol (2017) 0.75

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer (2017) 0.75

Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer (2017) 0.75

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell (2017) 0.75

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol (2017) 0.75

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adherence (2017) 0.75

The Utility of Serum CA9 for Prognostication in Prostate Cancer. Anticancer Res (2016) 0.75